Home / Leaderboard / Antecip Capital, L.L.C.
Antecip Capital, L.L.C.
Herriot Tabuteau · Family Office · Growth
Antecip Capital LLC is a private investment firm and holding company based in New York, founded by Dr. Herriot Tabuteau in 2003. Formerly known as Versant Capital Management LLC, the firm serves as a principal stockholder and private investment vehicle for Dr. Tabuteau, who is also the founder and CEO of Axsome Therapeutics. The institution focuses on strategic investments within the healthcare and biotechnology sectors, leveraging Dr. Tabuteau’s extensive background as a healthcare analyst and medical professional. The firm is characterized by its significant, long-term ownership positions in biopharmaceutical companies, particularly those involved in developing therapies for central nervous system disorders.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +75.7% |
| YTD return | +14.1% |
| Sharpe ratio | 3.07 |
| Win rate | 100% |
| AUM | $0.0B |
| Inception | Oct 1, 2025 |
| Updated | Sep 3, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $0.0B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | N/A |
Current Holdings
Updated on Sep 3, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| AXSM | Axsome Therapeutics Inc | 100.0% | +75.7% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Oct 1, 2025 | BUY | AXSM | 0.0% → 100.0% |
Investment Style Analysis
Antecip Capital, L.L.C. is widely recognized for employing a Growth strategy. As of Sep 3, 2026, the firm oversees approximately $0.0B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Oct 1, Antecip Capital, L.L.C. made a significant move by increasing exposure to AXSM. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
The firm’s investment philosophy is rooted in a high-conviction, long-term approach to the healthcare and life sciences sectors. It focuses on identifying and supporting innovative biotechnology companies with the potential to transform patient care. By utilizing deep medical and financial expertise, the firm seeks to provide foundational capital and strategic support to companies throughout their clinical development and commercialization phases. The strategy is characterized by concentrated holdings in a limited number of enterprises where the manager can apply specialized knowledge of genomics, instrumentation, and pharmaceutical preparations to drive value and advance medical innovation.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Antecip Capital, L.L.C..
Similar Investment Style
Based on Growth.
- Jaunty Global Limited — Alvin Jiang · 3M +30.1%
- Summit Partners, L.P. — Peter Y. Chung · 3M +42.1%
- Oberweis Asset Management, Inc. — James W. Oberweis · 3M -18.5%
- Hartline Investment Corporation — Brian W. Hart · 3M +1.8%
Frequently asked questions
How is the simulated portfolio for Antecip Capital, L.L.C. constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Antecip Capital, L.L.C.'s largest holding?
As of the latest filing, Antecip Capital, L.L.C.'s top position is Axsome Therapeutics Inc (AXSM), representing 100.0% of the portfolio. This reflects a high-conviction bet by the institution.
What is Antecip Capital, L.L.C.'s historical performance and risk profile?
Our simulation indicates a total return of +75.7% with a win rate of 100%. Notably, the portfolio maintains a Sharpe Ratio of 3.07, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Antecip Capital, L.L.C. primarily invest in?
Antecip Capital, L.L.C. has a strong preference for the Biotechnology sector, which makes up 100.0% of their disclosed assets. The portfolio also has exposure to other industries, indicating a specific thematic focus.
Is Antecip Capital, L.L.C.'s portfolio concentrated or diversified?
Antecip Capital, L.L.C. runs a highly concentrated portfolio with 1 disclosed positions. The top 3 holdings alone account for 100.0% of the total portfolio weight, suggesting a strategy that favors deep research into a few key names.
How has Antecip Capital, L.L.C. performed in 2026?
Our AI-simulated model portfolio for Antecip Capital, L.L.C. tracks a Year-to-Date (YTD) return of +14.1%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Herriot Tabuteau manage Antecip Capital, L.L.C. directly?
Yes, Herriot Tabuteau serves as the key portfolio manager for Antecip Capital, L.L.C., overseeing the investment strategy and final capital allocation decisions.